- Home
- RXRX
as 11-15-2024 4:00pm EST
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.0B | IPO Year: | 2021 |
| Target Price: | $9.40 | AVG Volume (30 days): | 5.5M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.89 - $15.74 | Next Earning Date: | 11-06-2024 |
| Revenue: | $65,184,000 | Revenue Growth: | 37.64% |
| Revenue Growth (this year): | 50.69% | Revenue Growth (next year): | 40.10% |
Stock Insider Trading Activity of Recursion Pharmaceuticals Inc. (RXRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Borgeson Blake | RXRX | Director | Oct 29 '24 | Sell | $6.72 | 11,447 | $76,926.13 | 7,077,560 | |
| Borgeson Blake | RXRX | Director | Oct 15 '24 | Sell | $6.67 | 11,447 | $76,326.31 | 7,077,560 | |
| Secora Michael | RXRX | Chief Financial Officer | Oct 8 '24 | Sell | $6.34 | 30,000 | $190,131.00 | 1,450,881 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Oct 2 '24 | Sell | $6.12 | 40,000 | $244,800.00 | 762,656 | |
| Borgeson Blake | RXRX | Director | Oct 1 '24 | Sell | $6.22 | 11,447 | $71,149.97 | 7,077,560 | |
| Marriott Tina | RXRX | President and COO | Sep 26 '24 | Sell | $7.00 | 6,000 | $42,004.80 | 521,138 | |
| Borgeson Blake | RXRX | Director | Sep 17 '24 | Sell | $6.84 | 11,447 | $78,332.97 | 7,077,560 | |
| Secora Michael | RXRX | Chief Financial Officer | Sep 10 '24 | Sell | $6.24 | 30,000 | $187,228.50 | 1,450,881 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Sep 4 '24 | Sell | $6.09 | 40,000 | $243,600.00 | 762,656 | |
| Borgeson Blake | RXRX | Director | Sep 3 '24 | Sell | $6.27 | 11,447 | $71,717.74 | 7,077,560 |
Latest Recursion Pharmaceuticals Inc. News
RXRX Breaking Stock News: Dive into RXRX Ticker-Specific Updates for Smart Investing
Investor's Business Daily
2 days ago
Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes
MT Newswires
4 days ago
Recursion Pharmaceuticals, Exscientia Shareholders Approve Proposed Combination
GlobeNewswire
4 days ago
Recursion and Exscientia Shareholders Approve the Proposed Combination
GlobeNewswire
4 days ago
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
Simply Wall St.
7 days ago
Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher
Zacks
10 days ago
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
Associated Press Finance
10 days ago
Recursion Pharmaceuticals: Q3 Earnings Snapshot
GlobeNewswire
10 days ago
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
Compare RXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXRX Recursion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.